Sun playing with GMP-violation fire; label changes drive flu vax delay;

> India-based Sun has again been slapped by the FDA for trouble in its U.S. business. Article

> Expect some flu vaccine delays now that three manufacturers are making label changes, warning U.S. healthcare providers that the syringe tip caps may contain natural rubber latex. Announcement

> A nuclear magnetic resonance technique underlies what Swedish researchers hope will become a small briefcase, into which pharmacists and customs officers can place a packet of tablets and a minute later find out whether the drug is authentic. Release

> Ombudsman programs and hotlines into neutral corporate territory, where individuals can confidentially report concerns, are ways to preserve the necessary independence of the QA group. Blog

> Bend Research has received a U.S. patent for its process that uses pressure nozzles to make spray-dried solid amorphous large-particle drug dispersions. Bend release

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.